PAINREFORM overview

TEL AVIV, Israel, April 10, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX), a clinical-stage specialty pharmaceutical company and developer of AI-powered energy optimization technologies, today announced its official expansion into the rapidly growing Smart Energy Management (SEM) sector. This move follows the successful acquisition of DeepSolar, a cutting-edge provider of AI-driven software solutions designed to optimize solar energy usage in residential and utility-scale solar power...

TEL AVIV, Israel, April 07, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd . (Nasdaq: PRFX) (" PainReform " or the " Company "), a specialty pharmaceutical company focused on the reformulation of established therapeutics and commercialization of the DeepSolar activities, today provided a business update for the year ended December 31, 2024. Ehud Geller, Chairman and interim Chief Executive Officer of PainReform, stated, "While we remain committed to advancing the clinical development of PRF-110, our...

TEL AVIV, Israel, March 05, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (" PainReform " or the " Company "), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the successful closing of its previously announced acquisition of 100% of the business activity of DeepSolar, an AI-driven solar analytics platform, from BladeRanger Ltd, a public company registered under the laws of the State of Israel, whose shares are...

DeepSolar brings new customer base in creation, including major utility-scale solar operators and independent power producers, while breaking into the residential solar market The Company remains committed to advancing its drug delivery technologies while broadening its growth potential TEL AVIV, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (" PainReform " or the " Company "), a clinical-stage specialty pharmaceutical company focused on the reformulation of...

TEL AVIV, Israel, Dec. 27, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (" PainReform " or the " Company "), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced an update regarding its Phase 3 clinical trial evaluating PRF-110 in post-surgical pain management of patients undergoing bunionectomy. PainReform previously disclosed initial topline data from its Phase 3 clinical trial in which it reported that it...

TEL AVIV, Israel, Nov. 20, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (" PainReform " or the " Company "), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the receipt of partial topline data from its contract research organization (CRO), Lotus Clinical Research ("Lotus"), for the Phase 3 clinical trial evaluating PRF-110 in post-surgical pain management of patients undergoing bunionectomy. Initial analysis...

This notification has no immediate effect on the listing or trading of PainReform’s ordinary shares on the Nasdaq Capital Market TEL AVIV, Israel, Nov. 07, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (" PainReform " or the " Company "), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that it has received a notification from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”)...

TEL AVIV, Israel, Sept. 11, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd . (Nasdaq: PRFX) (" PainReform " or the " Company "), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced positive findings regarding the compatibility of sutures in human clinical trials of its lead product, PRF-110. PRF-110 is designed to provide extended, non-opiate, post-surgical pain relief. The Company conducted comprehensive in vitro studies to assess...